Published in Hum Vaccin Immunother on April 14, 2014
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Mouse and human dendritic cell subtypes. Nat Rev Immunol (2002) 10.01
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood (2008) 3.95
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol (2001) 2.98
In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med (1999) 2.54
A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood (2005) 2.01
NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res (1998) 2.00
Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol (2002) 1.88
The cancer antigenome. EMBO J (2012) 1.78
IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol (2011) 1.76
Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol (2003) 1.53
Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol (2002) 1.49
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38
Spontaneous and continuous cyclooxygenase-2-dependent prostaglandin E2 production by stromal cells in the murine small intestine lamina propria: directing the tone of the intestinal immune response. J Immunol (2001) 1.27
Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol (1999) 1.26
Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One (2011) 1.23
Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol (2000) 1.20
CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br J Cancer (2003) 1.18
Human cutaneous dendritic cells migrate through dermal lymphatic vessels in a skin organ culture model. J Invest Dermatol (1996) 1.15
Dendritic cells under the spell of prostaglandins. Trends Immunol (2003) 1.08
Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother (2004) 1.08
Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. J Leukoc Biol (2005) 1.08
A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J Immunol (2006) 1.06
Dendritic cells, obtained from peripheral blood precursors in the presence of PGE2, promote Th2 responses. Adv Exp Med Biol (1997) 1.06
IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res (2001) 1.05
Transcriptional profiling of human dendritic cell populations and models--unique profiles of in vitro dendritic cells and implications on functionality and applicability. PLoS One (2013) 1.05
Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol (2002) 1.04
IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin Exp Immunol (2003) 1.03
IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer (2013) 1.01
Dendritic cell infiltration in colon cancer. J Immunother (2001) 1.00
Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res (2012) 0.95
Langerhans cells require signals from both tumour necrosis factor alpha and interleukin 1 beta for migration. Adv Exp Med Biol (1997) 0.93
Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology (2012) 0.90
Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol (2004) 0.87
IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation. PLoS One (2013) 0.87
Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins. Arch Dermatol Res (2000) 0.87
Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin Cancer Res (2011) 0.85
Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res (2006) 0.84
Tumor conditioned media from colorectal cancer patients inhibits dendritic cell maturation. Oncoimmunology (2012) 0.83
Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells. Br J Cancer (2001) 0.81
Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option. Immunobiology (2006) 0.79
Cancer: IL-22: linking inflammation and cancer. Nat Rev Drug Discov (2013) 0.76